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Objective—To determine which patients with near midline lesions may safely undergo unilateral
groin dissection based on clinical exam and lymphoscintigraphy (LSG) results.
Methods—Patients participating in GOG-173 underwent sentinel lymph node (SLN) localization
with blue dye, and radiocolloid with optional LSG before definitive inguinal-femoral
lymphadenectomy (LND). This analysis interrogates the reliability of LSG alone relative to
primary tumor location in those patients who had an interpretable LSG and at least one SLN
identified. Primary tumor location was categorized as lateral (>2 cm from midline), midline, or
lateral ambiguous (LA) if located within 2 cm., but not involving the midline.
Results—Two-hundred-thirty-four patients met eligibility criteria. Sixty-four had lateral lesions,
and underwent unilateral LND. All patients with LA (N=65) and midline (N=105) tumors
underwent bilateral LND. Bilateral drainage by LSG was identified in 14/64 (22%) patients with
lateral tumors, 38/65 (58%) with LA tumors and in 73/105 (70%) with midline tumors. At
mapping, no SLNs were found in contralateral groins among those patients with LA and midline
tumors who had unilateral-only LSGs. However, in these patients groin metastases were found in
4/32 patients with midline tumors undergoing contralateral dissection; none were found in 27
patients with LA tumors.
Conclusion—The likelihood of detectable bilateral drainage using preoperative LSG decreases
as a function of distance from midline. Patients with LA primaries and unilateral drainage on LSG
may safely undergo unilateral SLN.
Keywords
Vulva cancer; sentinel node; lymphadenectomy; lymphoscintigraphy; sentinel node mapping;
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INTRODUCTION
Primary carcinoma of the vulva is a rare gynecological malignancy afflicting less than 5000
women in the US annually [1]. Limited stage disease, which accounts for about half of these
cases, is primarily approached by surgical extirpation and lymphadenectomy. Refinements
in surgical technique and utility of appropriate adjuvant therapy have improved morbidity
and mortality from this disease [2–5]. However, chronic lower extremity edema - reported in
more than 30% of patients after groin lymphadenectomy – is a common post-operative
morbidity, which is difficult to manage and significantly impairs quality of life. (ref:
Gaarenstroom KN, et al., Int J Gynecol Cancer 13:522–527, 2003; DeHullu JA, et al., J
psychosom Obstet Gynecol 22:199–203, 2001). Therefore, the ability to identify a subset of
patients who might be able to undergo a less radical primary procedure would be of great
clinical benefit.
The clinical observation that lymphatic drainage from the vulva to the groin proceeds in
predictable fashion relative to the primary tumor location, has prompted the evaluation of
sentinel lymph node (SLN) assessment as an alternative to full inguinofemoral
lymphadenectomy. Currently, the most commonly used technique to identify sentinel nodes
uses intradermal injection of vital dye, followed by direct, open visualization and limited
groin exploration and node resection [6]. Outcomes data from two large observational
studies of SLN biopsy in women with limited stage disease have entered the public domain
[7,8]. While the two trials differed with respect to eligibility, mapping technique, utilization
of skill verification, primary endpoint and recommendation for groin dissection in the
presence of a metastatic SLN, they produced remarkably consistent results: the SLN biopsy
technique is feasible and is associated with a false negative predictive value of 3% or less in
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appropriately selected patients (T1 or T2 tumors less than 4 cm and clinically negative
groins).
Surgical recommendations regarding unilateral or bilateral groin dissection in patients with
clinically non-suspicious groins (N0, N1) are generally dictated by the location of vulvar
primary. Lesions more than 1–2 cm lateral to the midline structures are approached with
ipsilateral dissection; those within this boundary are approached with bilateral dissection.
The latter is recommended based on the increasing probability of contralateral flow when
lesions approach dermal lymphatics that may cross the midline. This concept is further
supported by studies demonstrating that contralateral groin failure in patients undergoing
ipsilateral groin dissection for these “lateralized” primaries is very low (<3%) [9,10]. Since
nodal metastases occur in the minority of women with early stage (T2) vulvar cancer (20 to
30%), and SLN localization techniques provide an opportunity to examine “real-time”
anatomical lymphatic drainage in these patients, we hypothesized that preoperative
lymphoscintigraphy could be useful in guiding groin dissection recommendations,
particularly for lesions within 2 cm, but not involving the midline. Herein, we report the
analysis of lymphoscintigraphy performed in patients participating in Gynecologic
Oncology Group (GOG) Protocol 173.
METHODS
Patients
The study design, preoperative and intraoperative testing and surgical procedures for this
study have been previously presented [8]. Briefly, women with biopsy confirmed squamous
cell carcinoma with T2 lesions less than 6 cm in greatest dimension and with clinically
negative (N0 or N1) groins were eligible to participate. Initially, patients meeting eligibility
were required only to have SLN localization via blue dye (20% of the sample population).
However, the study was amended two years following activation to require injection of
radiocolloid, with optional lymphoscintigraphy. Lymphoscintigraphy was performed prior to
surgery, following the intradermal injection of 0.5 to 1.0 ml of radiolabeled Tc99
microsulfur colloid at the leading border of the primary tumor (the border closest to the
groin). Injection on both sides of the tumor was required for patients with midline tumors.
Anatomical markers were placed on the symphysis pubis and anterior superior iliac spines,
which was followed by an immediately scan. The skin over a candidate SLN was marked
with an indelible marker. Transmission scans showing the outline of the body were
preferred, if possible. Other radionuclides were allowed as substitutions if Tc99 microsulfur
colloid was not available. EMLA cream was to be applied 30–60 minutes prior to the
injection of the radionuclide as a local anesthetic. These methods increased the frequency of
SLN detection. All enrolled patients underwent inguinofemoral lymphadenectomy following
SLN localization. Patients with clearly lateralized tumors underwent unilateral
lymphadenectomy. Those with primary tumors within 2 cm of the midline underwent
bilateral groin dissection. For this analysis, primary vulvar lesions were defined as lateral
(more than 2 cm from the midline), midline (tumor involving the midline) or lateral/
ambiguous (LA) (tumor not involving the midline but not meeting the criteria for a lateral
primary), based on hand-drawn pictorial representations of the primary tumor, tumor
description from operative notes and/or final pathology reports of the excised specimen.
Study Methodology
This prospective multi-institutional trial was conducted in 47 centers with no specific skill
verification and averaged about six cases per site during the enrollment period (December
1999 to December 2009). The primary statistical outcome measure of feasibility was the
false negative predictive value, which considered the rate of false negative identification
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(SLN histologically negative for metastases but with histologically metastatic non-sentinel
groin nodes) in affected groins and the true negative rate in unaffected dissected groins. The
staged enrollment design was based on the number of patients with histologically confirmed
groin node metastases maintaining a sensitivity of greater than 87% and a false negative
predictive value of under 5%.
GOG 173 accrued 515 assessable patients; the metastatic node rate was 32%.
Statistical Methods
The analysis set is comprised of eligible GOG 0173 patients with interpretable LSG (N =
234).
Pearson chi-square test was employed to assess statistical significance of observed
associations and/or trends among nominal variables [11]. Bar graphs and contingency tables
were used to summarize and display pertinent results. Estimated proportions are reported
with 95% confidence limits, where appropriate. Nominal data comparisons are made using
Chi Square test, including the analysis of trend for lateralized lesions and bilateral
lymphoscintigram uptake.
RESULTS
Figure 1 demonstrates how the 234 eligible candidates for this analysis were identified.
While 84 patients did not have a lymphoscintigram performed, the largest contributors to
inevaluability (N=126) were: uninterpretable study, study not submitted for review, if done,
or uniformative study due to no activity in the groin. Figure 2 demonstrates that the rate of
bilateral drainage on preoperative lymphoscintigram is significantly related to the location of
the primary tumor.
Lateral Primary Tumors
The relationship of preoperative lymphoscintigraphy, SLN localization, and final sentinel
and non-SLN groin histology in subjects with lateral primary lesions (n = 64) is presented in
Table 1. These patients all underwent a unilateral groin dissection on the ipsilateral side.
Lymphoscintigraphy identified drainage on only the ipsilateral side in 50/64 (78%), and
bilateral drainage in 14/64 (22%). At surgery, SLNs were identified in all of the dissected
ipsilateral groins. Of these SLNs, metastatic disease was identified in 11/64 (17%). Three
additional patients with pathologically negative SLNs were found with metastatic disease in
the excised non-sentinel nodal specimens (false negative SLNs).
Midline Primary Tumors
One-hundred-five patients had midline tumors, all of which invaded or occurred on midline
vulvar anatomical structures; all underwent bilateral groin dissections. The pattern of
lymphatic drainage identified by LSG, i.e. unilateral vs bilateral, was concordant with
patterns identified using dye/radiocolloid in 95/105 (90%) of cases. Unilateral drainage by
LSG was demonstrated in 32/105 (31%) patients. A SLN was found in all 32 of these
women; interestingly, no SLN was identified in the contralateral groin where the LSG
demonstrated no flow. In this cohort, metastatic nodal disease was found in 16 patients
(50%); one patient had a pathologically negative SLN but was found with metastatic disease
in the residual groin nodal tissue (6% false negative rate). Among the 73 patients with
bilateral drainage detected by lymphoscintigraphy, SLNs were identified by intraoperative
mapping bilaterally in 63 patients (86%), unilaterally in 6 (8%) and not identified in 4 (5%)
(Table 2). Among the 63 patients with SLN found in both groins, 18 had metastatic disease;
in three patients a pathologically unaffected SLN was identified in the presence of groin
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metastases in the excised residual nodal tissue (14% false negative rate). Among the six
patients with bilateral flow by LSG but unilaterally identified SLNs, no metastatic disease
was identified in either the SLN or the residual groin nodal tissue. Among the four patients
without a SLN identified, two were found with groin metastases. The overall rate of
metastatic disease for women with midline tumors was 41% (43/105 patients). Thus,
although data from this subset supports the accuracy of LSG, it does not clearly identify a
subset of patients in whom the technology could be used to restrict the scope of the initial
operative procedure.
Midline Primary Tumors Not Invading Midline Structures (Lateral/Ambiguous)
—There were 65 patients with lateral/ambiguous primary tumors. Preoperative LSG showed
unilateral drainage in 27/65 (42%) of subjects all of whom had a SLN identified,
ipsilaterally. Among these patients 10 (37%) were found with metastatic groin pathology –
all in ipsilateral groins. The SLN had metastatic disease in nine of these 10 cases (1 false
negative). No SLNs were identified at mapping on the side that had no detectable drainage
by LSG, and there were no positive nodes on the contralateral side in these fully dissected
groins. Among patients with bilateral LSG drainage, SLNs were found on one side in 14/38
(38%) and on both sides in 23/38 (62%) of patients. The node positivity rate was 40% in this
group and there was only one false-negative case.
DISCUSSION
In this study of lymphoscintigraphy performed as specified in GOG 173, we documented the
following: primary squamous cell tumors between 2 and 6 cm in greatest dimension can
have variable and ambiguous lymphatic drainage; that this drainage is related to primary
location relative to the midline; that preoperative assessment with lymphoscintigraphy may
inform the surgical approach in patients with lateral/ambiguous primary tumors. This latter
hypothesis is important because, if validated, it would impact a significant number of
patients (approximately 16% or 27/170), who by the nature of their primary lesion would
otherwise undergo unnecessary SLN biopsy and/or bilateral groin dissection. This is because
tumors within 2 cm of the midline are surgically managed as “midline” lesions with the
contemporary standard surgical approach of bilateral groin node dissection.
It should be cautioned, though, that lack of bilateral drainage in true midline lesions could
not be used with the same degree of confidence. In the current analysis, 30% of women with
tumor invading or crossing the midline had unilateral drainage by lymphoscintigraphy. In
these cases, although no SLNs were identified, four patients had metastatic disease in the
contralateral groin.
Historically, LSG was first employed in patients with truncal melanoma to help focus
locations where lymph node dissection should be performed. In these cases, potential
preferred drainage sites could be in the axillae, groin or both [12]. We wished to test the
hypothesis that lymphoscintigraphy could be similarly informative in ambiguously located
primary squamous vulva carcinomas.
We recognize the limitations of the current study, which was conducted to raise important
new hypotheses with regard to the SLN procedure in the care of women with primary vulvar
cancer. One significant limitation is the fact that lymphoscintigraphy was collected in less
than half of enrolled subjects. This might overestimate the proportion of informative cases in
each of the categories reviewed. However, the node-positive rate and negative predictive
value for the current study population was similar to that reported in GOG 173. Another
limitation is the lack of follow-up data on adjuvant treatment and recurrence rates. It is
appropriately inferred that false negative SLN assessment would lead to higher rates of groin
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recurrence relative to those with full groin dissection, particularly if untreated adjuvantly.
However, in GOG 173 all patients undergoing SLN localization, whether or not a SLN was
identified, were to undergo a full inguinal-femoral lymphadenectomy in that groin. It is
therefore not possible to estimate the impact of SLN biopsy alone in this sample. Similarly,
the absence of recurrence information also makes the evaluation of the cases of lateral
primary lesion with bilateral drainage on lymphoscintigraphy (in whom only unilateral
dissections were done) impossible. Ultimate recurrence in these undissected groins would
strengthen the predictive power of the study with regard to preoperative surgical treatment
planning. Fortunately, an ongoing multi-cooperative group trial (GROINS-VII/GOG-270,
NCT01500512) is evaluating a cohort of SLN negative patients who are managed without
groin dissection or adjuvant treatment for the primary endpoint of groin recurrence.
The seminal work by US and European investigators demonstrating the feasibility of
performing SLN evaluation for women with early stage vulvar cancer is continuing to
investigate surgical modification in this disease. The morbidity from routine
lymphadenectomy, particularly in combination with radiation or chemoradiation, is not
trivial and is a major cause of reduction in quality of life for these women [13]. The
GROINS-VII/GOG270 protocol will additionally evaluate the role of SLN biopsy and
directed radiation for small nodal metastases (less than 2 mm). The absence of full
lymphadenectomy is a distinct departure from current treatment recommendations, but has
the potential to improve outcomes and quality of life if proved feasible.
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• Lymphoscintigraphy can serve as a useful adjuvant tool in sentinel lymph node
biopsy planning
• Primary lateral ambiguous (LA) vulvar cancers have variable lymphatic
drainage including exclusively ipsilateral groin localization by
lymphoscintigraphy
• LA tumors with unilateral LSG drainage are at low risk for contralateral nodal
metastases and may avoid routine inguinal-femoral lymphadenectomy
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Figure 1. Consort diagram
CONSORT diagram demonstrating patient exclusions producing the study cohort of 234.
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Figure 2. Distribution of unilateral/bilateral localization by Lymphoscintography
Frequency of bilateral drainage by lymphoscintigraphy relative to the location of the
primary lesion as assessed by hand-drawn schematics, and operative or pathological reports.
There is significant reduction in bilateral drainage as the primary lesion moves lateral
(midline: 70%, lateral/ambiguous: 58%, lateral: 22%). However, we observed that more than
one in five patients with lateralized primary tumors (> 2 centimeters from the midline) had
bilateral drainage on lymphoscintigraphy.
Coleman et al. Page 10

























Coleman et al. Page 11
Table 1
Relationship of lymphoscintigraphy drainage to sentinel lymph node localization and final pathology in lateral
primary tumors (T2, less than 6 centimeters in greatest diameter, more than 2 centimeters from midline). All
patients underwent unilateral inguinal-femoral lymphadenectomy.
LATERAL
PRIMARY
Ipsilateral Contralateral Total (%)
LSG
drainage
50 (78%) 14 (22%) 64
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